FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940691444> ?p ?o ?g. }

• W2940691444 endingPage "13" @default.
• W2940691444 startingPage "1" @default.
• W2940691444 abstract "Biomarkers for treatment personalization in metastatic castration-resistant prostate cancer (mCRPC) could help improve patient outcomes. Multiple tests on blood have reported associations with poorer outcome, including serum lactate dehydrogenase (LDH), chromogranin A (CGA), neutrophil:lymphocyte ratio (NLR), and, recently, copy number (CN) of androgen receptor (AR) in plasma DNA. Biologic data suggest an association between choline uptake and AR signaling. We aimed to integrate 18F-fluorocholine (FCH) uptake on positron emission tomography/computed tomography (PET/CT) scanning with plasma AR CN and other routinely obtained circulating biomarkers to evaluate their association with outcome.We determined plasma AR CN by digital droplet polymerase chain reaction from 105 mCRPC samples collected before abiraterone (n = 65) or enzalutamide (n = 40) therapy in the before (n = 26) and after (n = 79) chemotherapy settings. Pretreatment serum LDH, CGA, and NLR were also measured. FCH-PET/CT scan was performed at baseline, and maximum standardized uptake value (SUVmax), total lesion activity (TLA), and metabolic tumor volume (MTV) were calculated. Main end points were the correlation of FCH-PET/CT parameters with circulating biomarkers and their impact on outcome.Plasma AR CN gain was observed in 27 patients (25.7%), and it correlated significantly with higher median SUVmax, TLA, and MTV values (P < .001). Kaplan-Meier curves showed significantly worse progression-free survival and overall survival in patients with plasma AR gain and higher SUVmax, TLA, and MTV values (P < .001 in each prognostic group). Conversely, no association was reported for prostate-specific antigen response. On multivariable analysis of overall survival, we showed as independent factors AR gain (hazard ratio [HR], 1.92; 95% CI, 1.07 to 3.47; P = .029), presence of visceral metastasis (HR, 3.04; 95% CI, 1.66 to 5.58; P = < .001), LDH (HR, 2.95; 95% CI, 1.72 to 5.05; P < .001), NLR (HR, 3.51; 95% CI, 2.14 to 5.74; P < .001), serum CGA (HR, 3.36; 95% CI, 1.99 to 5.67; P < .001), and MTV (HR, 2.09; 95% CI, 1.25 to 3.50; P = .005).Our results indicate the potential usefulness of integrating functional imaging with plasma DNA analysis and other noninvasive biomarkers as a tool to improve treatment selection for CRPC. A larger prospective evaluation is warranted." @default.
• W2940691444 created "2019-05-03" @default.
• W2940691444 creator A5000156180 @default.
• W2940691444 creator A5006130493 @default.
• W2940691444 creator A5030571299 @default.
• W2940691444 creator A5031994096 @default.
• W2940691444 creator A5042277842 @default.
• W2940691444 creator A5048745498 @default.
• W2940691444 creator A5056071446 @default.
• W2940691444 creator A5056449812 @default.
• W2940691444 creator A5058812950 @default.
• W2940691444 creator A5061064559 @default.
• W2940691444 creator A5061879497 @default.
• W2940691444 creator A5064728742 @default.
• W2940691444 creator A5071060598 @default.
• W2940691444 creator A5077647538 @default.
• W2940691444 creator A5087812629 @default.
• W2940691444 date "2019-12-01" @default.
• W2940691444 modified "2023-09-29" @default.
• W2940691444 title "Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis" @default.
• W2940691444 cites W1512308415 @default.
• W2940691444 cites W1757407923 @default.
• W2940691444 cites W1898749913 @default.
• W2940691444 cites W1916924456 @default.
• W2940691444 cites W2006352011 @default.
• W2940691444 cites W2019704592 @default.
• W2940691444 cites W2067312336 @default.
• W2940691444 cites W2110534364 @default.
• W2940691444 cites W2112104987 @default.
• W2940691444 cites W2117460748 @default.
• W2940691444 cites W2121098984 @default.
• W2940691444 cites W2137467802 @default.
• W2940691444 cites W2139855987 @default.
• W2940691444 cites W2148643283 @default.
• W2940691444 cites W2156923287 @default.
• W2940691444 cites W2159771669 @default.
• W2940691444 cites W2166918329 @default.
• W2940691444 cites W2181283187 @default.
• W2940691444 cites W2196689106 @default.
• W2940691444 cites W2376226802 @default.
• W2940691444 cites W2403998898 @default.
• W2940691444 cites W2495021631 @default.
• W2940691444 cites W2530956228 @default.
• W2940691444 cites W2567986926 @default.
• W2940691444 cites W2571250257 @default.
• W2940691444 cites W2605932829 @default.
• W2940691444 cites W2611922828 @default.
• W2940691444 cites W2734371126 @default.
• W2940691444 cites W2767565547 @default.
• W2940691444 cites W2781525129 @default.
• W2940691444 cites W2789730857 @default.
• W2940691444 cites W2808736367 @default.
• W2940691444 cites W2884296261 @default.
• W2940691444 cites W2898090458 @default.
• W2940691444 cites W3186365562 @default.
• W2940691444 doi "https://doi.org/10.1200/po.18.00302" @default.
• W2940691444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35100689" @default.
• W2940691444 hasPublicationYear "2019" @default.
• W2940691444 type Work @default.
• W2940691444 sameAs 2940691444 @default.
• W2940691444 citedByCount "7" @default.
• W2940691444 countsByYear W29406914442019 @default.
• W2940691444 countsByYear W29406914442021 @default.
• W2940691444 countsByYear W29406914442022 @default.
• W2940691444 countsByYear W29406914442023 @default.
• W2940691444 crossrefType "journal-article" @default.
• W2940691444 hasAuthorship W2940691444A5000156180 @default.
• W2940691444 hasAuthorship W2940691444A5006130493 @default.
• W2940691444 hasAuthorship W2940691444A5030571299 @default.
• W2940691444 hasAuthorship W2940691444A5031994096 @default.
• W2940691444 hasAuthorship W2940691444A5042277842 @default.
• W2940691444 hasAuthorship W2940691444A5048745498 @default.
• W2940691444 hasAuthorship W2940691444A5056071446 @default.
• W2940691444 hasAuthorship W2940691444A5056449812 @default.
• W2940691444 hasAuthorship W2940691444A5058812950 @default.
• W2940691444 hasAuthorship W2940691444A5061064559 @default.
• W2940691444 hasAuthorship W2940691444A5061879497 @default.
• W2940691444 hasAuthorship W2940691444A5064728742 @default.
• W2940691444 hasAuthorship W2940691444A5071060598 @default.
• W2940691444 hasAuthorship W2940691444A5077647538 @default.
• W2940691444 hasAuthorship W2940691444A5087812629 @default.
• W2940691444 hasBestOaLocation W29406914442 @default.
• W2940691444 hasConcept C121608353 @default.
• W2940691444 hasConcept C126322002 @default.
• W2940691444 hasConcept C126894567 @default.
• W2940691444 hasConcept C143998085 @default.
• W2940691444 hasConcept C199374082 @default.
• W2940691444 hasConcept C2775832370 @default.
• W2940691444 hasConcept C2775842073 @default.
• W2940691444 hasConcept C2776551883 @default.
• W2940691444 hasConcept C2777899217 @default.
• W2940691444 hasConcept C2780192828 @default.
• W2940691444 hasConcept C2989005 @default.
• W2940691444 hasConcept C61367390 @default.
• W2940691444 hasConcept C71924100 @default.
• W2940691444 hasConcept C90924648 @default.
• W2940691444 hasConceptScore W2940691444C121608353 @default.
• W2940691444 hasConceptScore W2940691444C126322002 @default.

• next